ReviewOpen forum infectious diseases2023
Relapsing Babesiosis With Molecular Evidence of Resistance to Certain Antimicrobials Commonly Used to Treat
Review in Open forum infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 10 citations in OpenAlex.
- A case-control study of blood group antigen expression in Babesia microti infected patients in the United States.Transfusion · 2026Article
- Natural products against Babesiosis: active compounds, molecular mechanisms, application limitations and translational development.Frontiers in cellular and infection microbiology · 2026Review
- A Prospective Cohort Longitudinal Study of Human Acute Babesiosis: Quality of Life and Severity of Symptoms Through 1-Year Follow-up.Open forum infectious diseases · 2025Article
- Improvements in Blood Profiles of Canines Naturally Infected with Triple Blood Pathogens (Animals : an open access journal from MDPI · 2024Article
- DoTropical medicine and infectious disease · 2024Article
- Tafenoquine for Relapsing Babesiosis: A Case Series.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Article
- Immune Mediators Important for a Protective Secondary Response toPathogens (Basel, Switzerland) · 2024Article
- Plasma Blood Levels of Tafenoquine following a Single Oral Dosage in BALBc Mice with AcutePathogens (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human babesiosis cases are emerging with an increased incidence and a wider geographic range worldwide. Relapsing babesiosis cases are becoming more frequently encountered in clinical practice associated with the use of immunosuppressive medications. The 2020 Infectious Diseases Society of America babesiosis guideline recommends at least 6 weeks of antimicrobial treatment for highly immunocompromised patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.